NCT01339663 - Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2012

Conditions

Recurrent MelanomaStage IV Melanoma

Interventions

DRUG

cyclophosphamide

Given IV

BIOLOGICAL

aldesleukin

Given SC

BIOLOGICAL

autologous tumor cell vaccine

Receive T-APC via IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

immunologic technique

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

polymerase chain reaction

Correlative studies

BIOLOGICAL

therapeutic autologous lymphocytes

Receive adoptively transferred CD8+ antigen-specific T cell clones via IV

Trial Locations (1)

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER